
Why Semaglutide Pens Cost More Than Vials: OneSource CEO Explains
Semaglutide injection pens command a higher price than vials primarily due to intricate manufacturing demands in sterile environments and advanced automation, as explained by OneSource Specialty Pharma CEO Neeraj Sharma. With GLP-1 drugs like semaglutide fueling a $34.5 billion market set to double by the mid-2030s, understanding these costs highlights the trade-offs for patient convenience. This guide breaks down the production process and its implications for diabetes and weight management therapies.







